Loading provider…
Loading provider…
Hematology & Oncology Physician in Chicago, IL
NPI: 1265753834Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Peter's Phone Numberphone_androidMobile
Get Peter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 90 | 259 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 36 | 61 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 27 | 189 |
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
Authors: Riedell, Peter A, Bishop, Michael R
Journal: Ther Adv Hematol
Publication Date: 2020-01-29
Authors: Justin Kline, Matthew Frigault, James Godfrey
Journal: Blood
Authors: Justin Kline, Satyajit Kosuri, Andrew Artz, Mariam Nawas, Andrzej Jakubowiak, Benjamin Derman
Journal: Blood Adv
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Ibrutinib, BIOLOGICAL: Rapcabtagene autoleucel single agent
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: BIOLOGICAL: tisagenlecleucel
Lead Sponsor: Emory University
Collaborators: National Cancer Institute (NCI), Novartis, Secura Bio, Inc.
Intervention / Treatment: DRUG: Duvelisib, BIOLOGICAL: Tisagenlecleucel